Type I interferon responses contribute to immune protection against mycobacterial infection
In @elife.bsky.social: Type I interferon responses contribute to immune protection against mycobacterial infection doi.org/10.7554/eLif...
#TBSky #IDSky #Immunosky
work led by Gillian Tomlinson with support from @mnoursad.bsky.social & @innate2adaptive.bsky.social group (1/5)
31.05.2025 12:22 โ ๐ 9 ๐ 4 ๐ฌ 1 ๐ 0
Lancet
Very excited to share our new piece of work in the Lancet Global Health @lancetgh.bsky.social โ Periskope-CM, a set of personalised risk prediction tools for HIV-associated cryptococcal meningitis mortality: www.thelancet.com/journals/lan...
#IDsky #HIV #GlobalHealth #meningitis #fungal
1/8
30.04.2025 19:59 โ ๐ 3 ๐ 2 ๐ฌ 1 ๐ 1
Come on down, anyone eligible for a post-doc do consider applying for this exciting project with @jennyrohn.bsky.social, @scottishwormboy.bsky.social & me!
Got a touch of #UTISky #IDSky #ImmunoSky & ๐งช about it! ๐
30.04.2025 21:39 โ ๐ 5 ๐ 6 ๐ฌ 0 ๐ 0
We also hope Metaclonotypist will prove to be a valuable application for fast and flexible parameter optimisation for identification of T cell metaclones across wide-ranging disease domains.
21.04.2025 17:28 โ ๐ 0 ๐ 0 ๐ฌ 0 ๐ 0
Given the critical role of T cell immunity in TB, we are excited about the potential for using generalisable T cell metaclones for improved disease-risk stratification in Mtb-infected people, and for identification of T cell epitopes for development of more effective vaccines.
21.04.2025 17:28 โ ๐ 0 ๐ 0 ๐ฌ 1 ๐ 0
Although the predominant repertoire of T cell reactivity to Mtb epitopes is private to individuals, we found striking evidence for population-wide immunodominance at the level of individual pMHC specificity revealed by highly generalisable/public T cell metaclones.
21.04.2025 17:28 โ ๐ 0 ๐ 0 ๐ฌ 1 ๐ 0
To overcome inter-individual TCR sequence diversity for shared peptide-MHC specific responses to Mtb , we developed a new computational pipeline, Metaclonotypist, to identify HLA-associated clusters of similar TCR sequences (metaclones) across a large ethnically diverse study population.
21.04.2025 17:28 โ ๐ 0 ๐ 0 ๐ฌ 1 ๐ 0
We used the tuberculin skin test as a standardised in vivo challenge comprising the whole Mtb proteome to generate localised enrichment of Mtb reactive T cells derived from the whole in vivo repertoire, which we characterised by TCR sequencing.
21.04.2025 17:28 โ ๐ 0 ๐ 0 ๐ฌ 1 ๐ 0
Dr Munyaradzi Musvosvi speaks about the Titan Vaccine Research Project which will allow selection of most promising TB vaccine candidates. This work is supported by the South African mRNA Vaccine Consortium & funded by @samrcza.bsky.social @tomscriba.bsky.social www.youtube.com/watch?v=zwPM...
15.04.2025 13:51 โ ๐ 4 ๐ 3 ๐ฌ 1 ๐ 0
YouTube video by SATVIUCT
Immunopathology of TB: Studying the role of the lymph nodes in the TB spectrum.
Immunopathology of TB: SATVI researchers discuss a groundbreaking study which investigates the role of lymph nodes in the context of mycobacterium tuberculosis infection and disease. The study was funded by a grant from
@wellcomeleap.bsky.social a program of youtu.be/8_gCOAfWUpw
15.04.2025 13:44 โ ๐ 2 ๐ 2 ๐ฌ 0 ๐ 0
2 weeks to the deadline for applications to this post.. take a look, get in touch if you want hear more, don't hold back๐
11.04.2025 08:18 โ ๐ 2 ๐ 5 ๐ฌ 0 ๐ 0
A logo showing a person and the words Be Part of Research
Academic Clinical Lecturer Posts in Infection now out: for people training in ID in UK & hold/imminently completing PhD.
2 posts @lshtm.bsky.social
shorturl.at/EIUIz
1 at St Georges & 1 at Kings
shorturl.at/8kDY3
If interested in @lshtm.bsky.social posts get in touch.
UK ID people please share!!
28.03.2025 14:54 โ ๐ 6 ๐ 12 ๐ฌ 0 ๐ 0
Weโre hiring! Looking for a laboratory post-doc fellow to help us disentangle protective and pathogenic T cells in TB, so we can stratify disease-risk after infection, and develop more effective vaccines. Interdisciplinary science in the heart of London. What's not to like? More here: bit.ly/4iIEiwu
27.03.2025 22:58 โ ๐ 8 ๐ 13 ๐ฌ 0 ๐ 2
This is a great initiative!
21.02.2025 16:47 โ ๐ 2 ๐ 1 ๐ฌ 0 ๐ 0
Fab analysis @hannahrickman.bsky.social - will we be well cited. are there sex-stratified data for house-hold contacts for which we may expect similar exposures?
10.01.2025 10:43 โ ๐ 2 ๐ 1 ๐ฌ 1 ๐ 0
State of the art in the enigmatic and complex world of immunological determinants of TB๐
14.12.2024 08:28 โ ๐ 1 ๐ 0 ๐ฌ 0 ๐ 0
Graphical summary of our paper. In mice, prior lower airway exposure to diverse inflammatory stimuli, including chronic bacterial infections such as M. tuberculosis, acute bacterial infections such as pulmonary S. aureus, viral infections such as Influenza A, type-II allergic responses such as the OVA-Alum model, activation of pulmonary TLR9 by CpG or pulmonary TLR1/2 by Pam3CSK4
leads to reduced viral burden upon subsequent infection with SARS-CoV-2 (SCV2). (2) This SCV2 restriction occurs prior to induction of SCV2-specific adaptive immune responses
and is mediated through innate immune responses, including the induction of IFN-I, TNFฮฑ and IL-1 and sustained changes to the TRM (Tissue resident macrophage) cellular
compartment and the pulmonary epithelium. (3) Innate cytokine and TLR signaling to both recruited immune cells and the pulmonary epithelium creates a microenvironment in the
lung that limits early replication of SCV2. IFN-I signaling to pulmonary ECs (epithelial cells) increases expression of interferon-stimulated genes, that likely cell-intrinsically limit viral
replication. TNF- or IL-1 suppress SCV2 independently of IFN-I signaling. TNF acts exclusively through radio-resistant cell types such as the lung epithelium, whereas IL-1 affords
control both direct and indirectly, through either stromal and hematopoietic cell types, to restrict overall early SCV2 burden.
Best #Nikolaus ๐
! Our paper on how the ๐ซ microenvironment can shape #innate immunity against #viruses is out @sciimmunology.bsky.social This was a herculean effort brilliantly led by @pauljbaker.bsky.social who singlehandedly established the model in the lab during the pandemic. ๐งช #Immunosky 1/9
06.12.2024 22:37 โ ๐ 295 ๐ 83 ๐ฌ 29 ๐ 9
Exciting- live to hear more!
04.12.2024 22:36 โ ๐ 1 ๐ 0 ๐ฌ 0 ๐ 0
important point- have not done this yet- wonder whether protein as dynamic as transcripts
03.12.2024 08:07 โ ๐ 1 ๐ 0 ๐ฌ 0 ๐ 0
and these data from unselected acute respiratory viruses in community acquired infection - with longitudinal sampling after the symptom onset
02.12.2024 13:12 โ ๐ 0 ๐ 0 ๐ฌ 0 ๐ 0
Not sure if I have misunderstood- our findings that distinct biomarkers discriminate early & late phases of infection were generalisable to all acute respiratory viruses we have been able to test - panel on right = extended time course from Flu challenge
02.12.2024 08:20 โ ๐ 0 ๐ 0 ๐ฌ 1 ๐ 0
this discovery would not have been possible without the detailed time course sampling anchored in a standardised experimental challenge ... as you rightly say lot's of other insights from this model - for convenience, links to these below:
01.12.2024 21:38 โ ๐ 4 ๐ 0 ๐ฌ 2 ๐ 1
Program Manager ID/TB/HIV/Cancer/Rare Diseases, US & International Research Projects
๐๐ฝ๐ถ๐โโฌ๐ธ๐ณ๐น๐
โ๏ธ๐ท๐โ๐ผ๐ป๐ฉป๐ฒ๐ฝ๐บ๐ธ
Treatment Action Group's Basic Science, Vaccines & Cure Project, by Richard Jefferys. ๐ณ๏ธโโง๏ธ
Primary Treatment Action Group account: https://bsky.app/profile/treatmentactiongroup.org
TAG website: https://www.treatmentactiongroup.org/
Director @modmedmicro.bsky.social; Previous Director @kemri_wellcome; Researcher on vaccines, malaria, viruses; Clinical Microbiologist, Infectious Disease, General Medicine
Welcome to the official Bluesky account for the New England Journal of Medicine!
Follow us for high-quality, peer-reviewed research and clinical content from the worldโs leading medical journal and website (NEJM.org).
We study innate immunity to respiratory viral infections at
@imperialcollegeldn.bsky.social, @imperialnhli.bsky.social, Section for Respiratory Infections
50:50 physician scientist
Infectious diseases/microbiology/penicillin allergy de-labelling
Fledgling lab studying immune perturbations in paediatric infections at UCL
Post-doc @pallettlab.bsky.social, Institute of Immunity and Transplantation, UCL โข investigating stromal-T cell communication in liver fibrosis โข he/him โข #immunology
PhD student at the Pallett lab, Div. Of Infection and Immunity, UCL. Studying the metabolism of liver resident T cells.
Melanoma oncologist at The Christie. Wellcome early career fellow at University of Manchester, The Francis Crick and UCL. Interested in tumour local and systemic immune changes, metastasis, ctdna and cancer evolution. Music, art, politics, hiking.
MSCA/UKRI Fellow studying B cells at @Tolarlab.bsky.social (@iit_ucl) | PhD (she/her) ๐ช๐ธ ๐ซ๐ฎ ๐ฌ๐ง | Immunology & Cell Biology | Seeing is believing ๐ฌTypos are my own.
Northern Irish postdoc @tolarlab.bsky.social, UCL | Interested in FDCs & B cells | he/him | ๐ฎ๐ช ๐ณ๏ธโ๐
tolarlab.com
Research Technician at the @pallettlab | MRes Experimental and Translational Immunology - UCL | BSc Medical Biosciences - ICL
Quantitative immunology lab (PI: Andreas Tiffeau-Mayer)
https://qimmuno.com/
We use ideas from the physics of living systems and machine learning to understand human adaptive immunity in health and disease.
Infectious Diseases specialist doctor (Royal Free London) and academic (UCL). Research focuses on preventing antimicrobial resistance and some fun stuff like phages ๐ฆ
Wellcome Trust Early Career Investigator allied with Jolly and Henriques labs based in UCL #Cellular #Microbiologist doing #LIVE/#SR #Microscopy of #HIV, #NuclearPores #Tcells and all things #Trafficking and #Host #Cell ?manipulation by #Pathogens!
Infection immunology PostDoc in the Jolly Lab at UCL. Views are my own.
News and views from the Jolly Lab in the Division of Infection and Immunity at UCL!
(Run by the lab.)
Postdoc in the Jolly lab @UCL studying T cell reprogramming by HIV-1 ๐ฌ๐ง | PhD on bat antiviral IFITMs @Edinburgh๐ฆ | virus-host interactions ๐ฆ | ๐ Hong Kong
Twitter @NellyMak_sc (for Sky Follower Bridge)
Molecular virology. Innate immunity. Piquant proclivities. Run by lab members.